What do systematic reviews say?

Cardiovascular mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

Cardiovascular morbidity · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

Total serious adverse events · patients with hypertension

Total serious adverse events · patients with hypertension

Total serious adverse events · patients with hypertension

Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles

Secondary outcome: all adverse events · People who may be at risk for primary hypertension

Proportion of participants diagnosed with hypertension at trial completion · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension

Heart rate · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension

Proportion of participants diagnosed with hypertension at trial completion · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension

Withdrawals due to adverse events · hypertension in adults with type 2 diabetes mellitus

Change** in pulse pressure (mmHg) · hypertension in adults with type 2 diabetes mellitus

Change** in heart rate (beats/min) · hypertension in adults with type 2 diabetes mellitus

Adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Acronyms and grades · Male participants

Acronyms and grades · Adult female participants with PCOS

Cerivastatin dose · participants with normal or abnormal lipid profiles

CI: confidence interval · participants with normal or abnormal lipid profiles

aMean baseline values. · participants with normal or abnormal lipid profiles

Cerivastatin dose · participants with normal or abnormal lipid profiles